S.Amdt. 1271Senate118th Congress (2023-2025)2nd degree
S.Amdt. 1271
Sponsored by
Sen. Kyrsten Sinema (I-AZ)
Submitted September 20, 2023
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Floor
Latest Action
Senate amendment submitted
September 20, 2023
View full timeline
Floor
Senate amendment submitted
September 20, 2023
Floor
Senate amendment submitted
September 20, 2023
Text
Submitted
SA 1271. Ms. SINEMA submitted an amendment intended to be proposed to amendment SA 1092 proposed by Mrs. Murray (for herself and Ms. Collins) to the bill H.R. 4366, making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; which was ordered to lie on the table; as follows: At the appropriate place in division A, insert the following: SEC. ___. REPORT ON FEASIBILITY OF STUDY BY DEPARTMENT OF VETERANS AFFAIRS ON PATIENT RESPONSES TO PHARMACEUTICALS BASED ON THEIR GENETIC PROFILE. (a) In General.--Not later than 90 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall submit to the appropriate committees of Congress a report on the feasibility, advisability, and cost estimate of undertaking a study to record patient responses to pharmaceuticals based on their genetic profile, which shall include the elements specified under subsection (b). (b) Elements of Study.--The elements specified under this subsection are-- (1) providing a patient with a pharmacogenomics test; (2) using the results of that test, through an integrated application programming interface platform, and mapping those results against-- (A) the medical condition or conditions of the patient; (B) the medications currently prescribed to the patient; and (C) different therapeutics or medications that are widely prescribed to treat such condition or conditions; (3) providing the treating physician of the patient with easily understood, actionable, digitized information to utilize in making a decision about the course of medication or medications that would yield the greatest benefit to the patient and limit the risk of potential harm or adverse events based upon identified drug-to-gene and drug-to-drug interactions; and (4) including an analysis on cost saving to the Department of Veterans Affairs and the patient. (c) Appropriate Committees of Congress Defined.--In this section, the term ``appropriate committees of Congress'' means-- (1) the Committee on Appropriations and the Committee on Veterans' Affairs of the Senate; and (2) the Committee on Appropriations and the Committee on Veterans' Affairs of the House of Representatives. ______